Format

Send to

Choose Destination
Fertil Steril. 2001 Feb;75(2):282-7.

The insulin-like growth factor-I system and hormone replacement therapy.

Author information

1
Hospital Regional Universitário de Maringá, Rua Joaquim Nabuco, 163-apt.602, Zona 1, 87013-340 Maringá, Paraná, São Paulo, Brazil.

Abstract

OBJECTIVE:

To determine the effects of hormone replacement therapy on plasma concentrations of free and total insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3.

DESIGN:

Clinical study.

SETTING:

Gynecologic clinic at a university hospital.

PATIENT(S):

Seventy-one postmenopausal women.

INTERVENTION(S):

Six cycles of four different hormonal replacement therapy regimens: oral conjugated estrogens, transdermal estradiol, oral conjugated estrogens and norethisterone, and transdermal estradiol and norethisterone acetate.

MAIN OUTCOME MEASURE(S):

Blood samples were collected before and after treatment for measurement of free and total IGF-I, IGFBP-1, and IGFBP-3.

RESULT(S):

Conjugated estrogen replacement therapy is associated with a decrease in plasma concentration of total IGF-I and increase in concentrations of free IGF-I and IGFBP-1. Transdermal estrogens have no effect on total and free IGF-I and IGFBP-1 concentrations. Oral norethisterone plus conjugated estrogens increased free IGF-I and IGFBP-1 concentrations but did not change IGF-I concentrations. Transdermal conjugated estrogens plus norethisterone acetate increased free IGF-I concentrations but not total IGF-I or IGFBP-1 concentrations. The plasma concentration of IGFBP-3 did not change in any group.

CONCLUSION(S):

Alterations in total IGF-I concentration can occur depending on the route of hormone replacement therapy administration. Free IGF-I concentrations were elevated in all study groups except that treated with transdermal estrogens.

PMID:
11172828
DOI:
10.1016/s0015-0282(00)01691-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center